mwb research raises target for Drägerwerk stock to EUR 135.00

Published on 10/13/2026 at 13:52 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Second-quarter revenue reached EUR 847.30 million, up 8.60 percent. Drägerwerk stock is EUR 116.10 on October 13, 2026, up 0.26 percent versus Xetra close.

mwb research raised its Drägerwerk target to EUR 135.00 on October 9, 2026, from EUR 130.00.
Second-quarter revenue reached EUR 847.30 million, up 8.60 percent year over year.
Drägerwerk stock was EUR 116.10 at Lang & Schwarz on October 13, 2026 at 1:42 p.m. CEST, 0.26 percent above the Xetra close of October 12, 2026.
Third-quarter results are scheduled for October 29, 2026, while the price-to-earnings ratio is 12.71.

Architekturvisualisierung eines modernen Medizintechnik-Forschungsgebäudes mit Glasfassade — Drägerwerk AG & Co. KGaA modernes Forschungsgebäude Medizintechnik Glasfassade Architekturrender Unternehmensanlage DE0005550636, Illustration mit AI erstellt.

mwb research raised its Drägerwerk target from EUR 130.00 to EUR 135.00 on October 9, 2026, according to FinanzNachrichten. The new target lies 16.28 percent above the EUR 116.10 Lang & Schwarz price. Drägerwerk stock was trading at EUR 116.10 at Lang & Schwarz on October 13, 2026 at 1:42 p.m. CEST, 0.26 percent above the Xetra close of October 12, 2026 at EUR 115.80.

Revenue accelerated in the second quarter

Drägerwerk reported EUR 847.30 million in revenue for the second quarter of 2026, up 8.60 percent from EUR 779.99 million in the year-ago quarter, Aktienmagazin reported. Net income rose 162.10 percent to EUR 29.50 million from EUR 11.26 million, giving the company a stronger earnings base ahead of the next reporting date.

Price stays 7.42 percent below its high

The Lang & Schwarz price is 7.42 percent below the 52-week high of EUR 125.40 and remains inside a range that extends down to EUR 66.00. The market capitalization is EUR 2.2 billion, while the price-to-earnings ratio is 12.71 as of October 13, 2026.

The investor-relations page says Drägerwerk expects currency-adjusted revenue growth of 2.00 to 6.00 percent and an EBIT margin of 5.00 to 7.50 percent in fiscal year 2026, Drägerwerk states. The next quarterly results are scheduled for October 29, 2026, and the Capital Markets Day is set for November 18, 2026, according to Marketscreener.

Comparison with peers

Drägerwerk (Xetra, EUR): plus 0.26 percent, P/E 12.71, market capitalization EUR 2.2 billion.
Sartorius (Xetra, EUR): minus 0.83 percent, P/E 88.73, market capitalization EUR 17.3 billion.
Fresenius Medical Care (Xetra, EUR): plus 0.24 percent, P/E 11.44, market capitalization EUR 10.1 billion.

Trading level on October 13

Drägerwerk stock was trading at EUR 116.10 at Lang & Schwarz on October 13, 2026 at 1:42 p.m. CEST, 0.26 percent above the Xetra close of October 12, 2026 at EUR 115.80. The price is 7.42 percent below the 52-week high of EUR 125.40.

The further course of trading is shown by the continuously updated real-time quote of Drägerwerk stock.